WO2009009114A3 - Compositions and methods for treating and diagnosing cancer - Google Patents

Compositions and methods for treating and diagnosing cancer Download PDF

Info

Publication number
WO2009009114A3
WO2009009114A3 PCT/US2008/008499 US2008008499W WO2009009114A3 WO 2009009114 A3 WO2009009114 A3 WO 2009009114A3 US 2008008499 W US2008008499 W US 2008008499W WO 2009009114 A3 WO2009009114 A3 WO 2009009114A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
treating
present
integrin beta
Prior art date
Application number
PCT/US2008/008499
Other languages
French (fr)
Other versions
WO2009009114A2 (en
Inventor
Sanjeev Satyal
Timothy Hoey
Lucas Donigian
Original Assignee
Oncomed Pharm Inc
Sanjeev Satyal
Timothy Hoey
Lucas Donigian
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncomed Pharm Inc, Sanjeev Satyal, Timothy Hoey, Lucas Donigian filed Critical Oncomed Pharm Inc
Publication of WO2009009114A2 publication Critical patent/WO2009009114A2/en
Publication of WO2009009114A3 publication Critical patent/WO2009009114A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Abstract

The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular, the present invention identifies integrin beta (1) as a cancer stem cell marker. In certain embodiments, the present invention provides a method of treating cancer comprising administering a therapeutically effective amount of an integrin beta (1) antibody. In certain embodiments, the integrin beta (1) antibody reduces the frequency of cancer stem cells in a solid tumor.
PCT/US2008/008499 2007-07-12 2008-07-11 Compositions and methods for treating and diagnosing cancer WO2009009114A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94932607P 2007-07-12 2007-07-12
US60/949,326 2007-07-12

Publications (2)

Publication Number Publication Date
WO2009009114A2 WO2009009114A2 (en) 2009-01-15
WO2009009114A3 true WO2009009114A3 (en) 2009-03-26

Family

ID=40229354

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/008499 WO2009009114A2 (en) 2007-07-12 2008-07-11 Compositions and methods for treating and diagnosing cancer

Country Status (1)

Country Link
WO (1) WO2009009114A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010099918A1 (en) * 2009-03-06 2010-09-10 Klaus Tschira Stiftung Ggmbh Pharmaceutical composition and method for identifying a cancerous and/or an inflammatory disease in a patient
EP2688585B1 (en) * 2011-03-23 2018-09-05 The Regents of The University of California Methods and compositions for improving antiangiogenic therapy with anti-integrins
WO2013119923A1 (en) 2012-02-09 2013-08-15 The Regents Of The University Of Michigan Different states of cancer stem cells
AU2013370467B2 (en) * 2012-12-26 2018-10-04 Oncosynergy, Inc. Anti- integrin beta1 antibody compositions and methods of use thereof
CN104761634B (en) * 2015-03-27 2018-05-18 李翀 A kind of pulmonary cancer diagnosis marker, antibody and its application
JP6935883B2 (en) * 2018-07-13 2021-09-15 五稜化薬株式会社 Pretreatment method for fluorescence image diagnosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087981A2 (en) * 2000-05-18 2001-11-22 Japan Tobacco, Inc. Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
US20070010469A1 (en) * 2000-06-02 2007-01-11 Chan Vivien W Gene products differentially expressed in cancerous cells III

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001087981A2 (en) * 2000-05-18 2001-11-22 Japan Tobacco, Inc. Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
US20070010469A1 (en) * 2000-06-02 2007-01-11 Chan Vivien W Gene products differentially expressed in cancerous cells III

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TAKADA ET AL.: "Identification of a regulatory region of integrin beta 1 subunit using activating and inhibiting antibodies.", J BIOL CHEM., vol. 268, no. 23, 15 August 1993 (1993-08-15), pages 17597 - 601 *

Also Published As

Publication number Publication date
WO2009009114A2 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
WO2007053648A3 (en) Compositions and methods for treating and diagnosing cancer
WO2008036419A3 (en) Aldehyde dehydrogenase 1(aldh1) as a cancer stem cell marker
WO2005005601A3 (en) Compositions and methods for treating and diagnosing cancer
WO2008103470A3 (en) Oncogenic-ras-signal dependent lethal compounds
WO2007053577A3 (en) Compositions and methods for diagnosing and treating cancer
WO2006004910A3 (en) Improved bispecific antibodies
WO2007009191A8 (en) Method for treating cancer
WO2008060788A3 (en) Compositions, methods, and devices for treating liver disease
WO2006138275A3 (en) Compositions and methods for treating and diagnosing cancer
WO2007118214A3 (en) Antibody compositions and methods for treatment of neoplastic disease
WO2009009114A3 (en) Compositions and methods for treating and diagnosing cancer
WO2010019702A3 (en) Ddr1-binding agents and methods of use thereof
BRPI0607203A2 (en) isolated anti-cd30 antibody, host cell, methods for inhibiting cd30 + cell growth, and use of a defucosylated anti-cd30 antibody
WO2007067992A3 (en) Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1
WO2008019376A3 (en) Compositions and methods using anti-cs1 antibodies to treat multiple myeloma
WO2007145840A3 (en) Compositions and methods for diagnosing and treating cancer
WO2007087453A3 (en) Compositions and methods for treating haematological proliferative disorders
WO2009073533A3 (en) Anti-b7h4 monoclonal antibody-drug conjugate and methods of use
WO2006018836A3 (en) Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
MX2009002065A (en) A pharmaceutical composition for treating lung cancer, a method for inhibiting growth or invasion of lung cancer and a method for treating lung cancer.
WO2007037653A8 (en) Use of mesenchymal stem cells genetically modified to express a suicide gene for treating a cancer
WO2008100328A3 (en) METHODS AND COMPOSITIONS FOR TARGETING gC1qR/p32
WO2006093857A3 (en) Method of providing readily available cellular material derived from peripheral blood and a composition thereof
WO2008112003A3 (en) Targeted binding agents directed to pdgfr-alpha and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08780112

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08780112

Country of ref document: EP

Kind code of ref document: A2